Items tagged with Treatment
Updates from the 1/4/6x24 Campaign (post with simple image)
A few recent Campaign updates from Treatment Action Group and allies.
Contact david.branigan@treatmentactiongroup.org for more information on how to be part of the 1/4/6x24 Campaign.
TAG's 2022 Pipeline Report: TB Treatment (post with simple image)
Treatment Action Group launches the 2022 Tuberculosis Treatment Pipeline Report.
Action needed to scale up access to shorter, safer TB prevention and treatment regimens (post with simple image)
A push to include the latest WHO-recommended TB regimens in the current round of funding requests to the Global Fund.
1/4/6x24 Campaign videos & World TB Day Toolkit (post with simple image)
Treatment Action Group and the 1/4/6x24 Campaign Coalition launch the 1/4/6x24 World TB Day Toolkit to support advocacy the week of World TB Day for access to shorter, safer regimens for TB prevention and treatment.
The 1/4/6×24 Campaign Coalition welcomes India’s rejection of Johnson & Johnson’s patent evergreening tactic (post with simple image)
The Indian Patent Office takes a laudable step that will pave the way for generic manufacturing of a key TB drug.
Advocacy campaign and petition call for universal access to six-month drug-resistant TB cures (post with simple image)
The Fast Track the Cure campaign demands universal access to six-month drug-resistant TB cure by 2024.
MSF demands J&J give up its patent monopoly on TB drug to put lives over profits (post with simple image)
Access to TB drug bedaquiline, a backbone medicine for drug-resistant TB treatment regimens, remains out of reach for too many.
Nitrosamines and TB medicines information note (post with simple image)
TAG and IMPAACT4TB project partners release several materials to explain how the identification of nitrosamines in rifampicin and rifapentine may affect the safety and supply of TB medicines, and what this may mean for TB programs and patients.
WHO publishes information notes on the use of bedaquiline and delamanid in children and adolescents with drug-resistant TB (post with simple image)
The information notes complement the updated WHO guidelines and operational handbook on the management of TB in children and adolescents released in 2022.
Urgent action necessary for equitable access to bedaquiline in all countries with high burdens of TB, MDR-TB, and TB/HIV (post with simple image)
Advocates demand that Johnson & Johnson commit to non-enforcement of secondary patent on bedaquiline so that access to generic, quality-assured bedaquiline is guaranteed after the primary patent expires on 18 July 2023.
Page 105 of 108 · Total posts: 0
←First 104 105 106 Last→